Dyphylline

Summary

Dyphylline (CHEMBL1752) is an approved small-molecule bronchodilator agent (ATC R03DA51); indicated across 1 condition including obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03DA51 (+1 more)
• Indications: 1 condition
• Chemistry: 254.24 Da · C10H14N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1752
Name	Dyphylline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3182
ChEBI	CHEBI:4728
ATC	R03DA51, R03DA01
Molecular formula	C10H14N4O4
Molecular weight	254.24
InChIKey	KSCFJBIXMNOVSH-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O

IUPAC name: 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione

ChEBI definition: An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.

Pharmacological roles (ChEBI): bronchodilator agent, vasodilator agent, EC 3.1.4.* (phosphoric diester hydrolase) inhibitor, muscle relaxant.

Also known as: Dilor, Dilor-400, Diprofilina, Diprophylline, Dyphilline, Dyphylline, Lufyllin, Neothylline, NSC-14305, SID855557, DYPHYLLINE, SID56422180

Patent coverage: 2,647 distinct patent families (9,152 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Survival motor neuron protein, Beta-lactamase, DNA polymerase beta.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SMN1	5.95	Potency	1122	nM	CHEMBL_ACT_3893441

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).